Trifluridine/Tipiracil and Talazoparib for Advanced Colorectal or Gastroesophageal Cancer
Phase 1
45
about 5.8 years
18+
1 site in NY
About this study
This trial is testing the safety and best dose of talazoparib when combined with trifluridine/tipiracil in people with advanced colorectal or gastroesophageal cancer. The goal is to determine how these drugs work together to stop tumor growth.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Talazoparib Tosylate
- 2.Take Trifluridine and Tipiracil Hydrochloride
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Antineoplastic Agent [TC] (Poly(ADP-Ribose) Polymerase Inhibitors), Antineoplastic Agent [TC] (Thymidine Phosphorylase Inhibitors), trifluridine
oral, ocular (Ophthalmic Solution)
Primary: Incidence of Adverse Events, Maximum tolerated dose/ recommended phase II dose
Secondary: CEA response rate (colorectal cancer patients), Overall Response Rate (ORR), Overall Survival (OS), Plasma Concentration (Cmax), Progression Free Survival (PFS), Progressive Disease Assessment (PD)
Gastroenterology, Oncology